Annual EBITDA
-$2.49 M
-$2.30 M-1237.57%
31 December 2023
Summary:
BioNexus Gene Lab annual earnings before interest, taxes, depreciation & amortization is currently -$2.49 million, with the most recent change of -$2.30 million (-1237.57%) on 31 December 2023. During the last 3 years, it has fallen by -$3.86 million (-280.69%). BGLC annual EBITDA is now -280.69% below its all-time high of $1.38 million, reached on 01 December 2020.BGLC EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$1.29 M
-$1.58 M-543.39%
30 September 2024
Summary:
BioNexus Gene Lab quarterly earnings before interest, taxes, depreciation & amortization is currently -$1.29 million, with the most recent change of -$1.58 million (-543.39%) on 30 September 2024. Over the past year, it has increased by +$1.21 million (+48.44%). BGLC quarterly EBITDA is now -218.57% below its all-time high of $1.09 million, reached on 01 March 2020.BGLC Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$759.90 K
+$1.21 M+61.44%
30 September 2024
Summary:
BioNexus Gene Lab TTM earnings before interest, taxes, depreciation & amortization is currently -$759.90 thousand, with the most recent change of +$1.21 million (+61.44%) on 30 September 2024. Over the past year, it has increased by +$2.11 million (+73.52%). BGLC TTM EBITDA is now -155.25% below its all-time high of $1.38 million, reached on 01 December 2020.BGLC TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BGLC EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -1237.6% | +48.4% | +73.5% |
| 3 y3 years | -280.7% | -422.5% | -176.3% |
| 5 y5 years | -2572.8% | -2757.0% | -395.1% |
BGLC EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -280.7% | at low | -422.5% | +48.4% | -165.3% | +73.5% |
| 5 y | 5 years | -280.7% | at low | -218.6% | +48.4% | -155.3% | +73.5% |
| alltime | all time | -280.7% | at low | -218.6% | +48.4% | -155.3% | +73.5% |
BioNexus Gene Lab EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.29 M(-543.4%) | -$759.90 K(-61.4%) |
| June 2024 | - | $290.60 K(-688.3%) | -$1.97 M(-21.5%) |
| Mar 2024 | - | -$49.40 K(-117.2%) | -$2.51 M(+0.9%) |
| Dec 2023 | -$2.49 M(+1237.6%) | $287.40 K(-111.5%) | -$2.49 M(-13.4%) |
| Sept 2023 | - | -$2.50 M(+909.4%) | -$2.87 M(+600.8%) |
| June 2023 | - | -$247.60 K(+859.7%) | -$409.40 K(+50.0%) |
| Mar 2023 | - | -$25.80 K(-73.3%) | -$272.90 K(+46.9%) |
| Dec 2022 | -$185.80 K(-116.0%) | -$96.60 K(+145.2%) | -$185.80 K(-234.2%) |
| Sept 2022 | - | -$39.40 K(-64.5%) | $138.40 K(-76.0%) |
| June 2022 | - | -$111.10 K(-281.2%) | $577.30 K(-33.5%) |
| Mar 2022 | - | $61.30 K(-73.1%) | $868.20 K(-25.4%) |
| Dec 2021 | $1.16 M | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | - | $227.60 K(-43.0%) | $1.16 M(+16.8%) |
| Sept 2021 | - | $399.50 K(+122.2%) | $996.30 K(+17.6%) |
| June 2021 | - | $179.80 K(-49.7%) | $847.50 K(+31.2%) |
| Mar 2021 | - | $357.20 K(+497.3%) | $646.00 K(-53.0%) |
| Dec 2020 | $1.38 M(-718.4%) | $59.80 K(-76.1%) | $1.38 M(+9.1%) |
| Sept 2020 | - | $250.70 K(-1255.3%) | $1.26 M(+30.6%) |
| June 2020 | - | -$21.70 K(-102.0%) | $965.50 K(+4.0%) |
| Mar 2020 | - | $1.09 M(-2097.6%) | $928.40 K(-546.6%) |
| Dec 2019 | -$222.40 K(-321.3%) | -$54.40 K(+20.6%) | -$207.90 K(+35.4%) |
| Sept 2019 | - | -$45.10 K(-23.3%) | -$153.50 K(+41.6%) |
| June 2019 | - | -$58.80 K(+18.5%) | -$108.40 K(+118.5%) |
| Mar 2019 | - | -$49.60 K | -$49.60 K |
| Dec 2018 | $100.50 K | - | - |
FAQ
- What is BioNexus Gene Lab annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for BioNexus Gene Lab?
- What is BioNexus Gene Lab annual EBITDA year-on-year change?
- What is BioNexus Gene Lab quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for BioNexus Gene Lab?
- What is BioNexus Gene Lab quarterly EBITDA year-on-year change?
- What is BioNexus Gene Lab TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for BioNexus Gene Lab?
- What is BioNexus Gene Lab TTM EBITDA year-on-year change?
What is BioNexus Gene Lab annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of BGLC is -$2.49 M
What is the all time high annual EBITDA for BioNexus Gene Lab?
BioNexus Gene Lab all-time high annual earnings before interest, taxes, depreciation & amortization is $1.38 M
What is BioNexus Gene Lab annual EBITDA year-on-year change?
Over the past year, BGLC annual earnings before interest, taxes, depreciation & amortization has changed by -$2.30 M (-1237.57%)
What is BioNexus Gene Lab quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of BGLC is -$1.29 M
What is the all time high quarterly EBITDA for BioNexus Gene Lab?
BioNexus Gene Lab all-time high quarterly earnings before interest, taxes, depreciation & amortization is $1.09 M
What is BioNexus Gene Lab quarterly EBITDA year-on-year change?
Over the past year, BGLC quarterly earnings before interest, taxes, depreciation & amortization has changed by +$1.21 M (+48.44%)
What is BioNexus Gene Lab TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of BGLC is -$759.90 K
What is the all time high TTM EBITDA for BioNexus Gene Lab?
BioNexus Gene Lab all-time high TTM earnings before interest, taxes, depreciation & amortization is $1.38 M
What is BioNexus Gene Lab TTM EBITDA year-on-year change?
Over the past year, BGLC TTM earnings before interest, taxes, depreciation & amortization has changed by +$2.11 M (+73.52%)